LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program

Topline data expected in 1Q 2028Phase 2bipolar depression trial initiation follows positive Phase 2 results in acute schizophreniaNEW YORK, Jan.

LB Pharmaceuticals initiates Phase 2 trial of LB-102

LB Pharmaceuticals (LBRX) announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients with bipolar depression. LB-102, a novel, once-daily, oral ...
Seeking Alpha

LB Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial of LB-102 in Schizophrenia

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of psychiatric diseases including ...
The Manila Times

LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

LB Pharmaceuticals, Inc ('LB Pharmaceuticals” or the 'Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company ...
Business Wire

Segal Trials Leads Phase 2 Schizophrenia Trial of LB-102 Toward Primary Endpoint

MIAMI LAKES, Fla.--(BUSINESS WIRE)--Segal Trials, a privately held clinical research network specializing in acute schizophrenia and other psychiatric disorders, has released enrollment performance ...